B
Biologics
A patient-focused platform for managing the financial, emotional, and physical burdens of cancer treatment
About Biologics
In 1994, a company named Biologics was founded in North Carolina with a focused mission: to improve the lives of people fighting cancer. The company operated as an oncology pharmacy services company, aiming to streamline the fragmented and complex world of cancer care for patients, healthcare providers, and pharmaceutical companies. By managing the distribution of oncology drugs and providing patient support services, Biologics created a more efficient and humane approach to care management. The company established itself as a key player in the specialty pharmacy sector, focusing specifically on oncology and other complex therapeutic areas. This specialization allowed them to develop deep expertise and build strong partnerships. Under the leadership of President and CEO Stuart Frantz, Biologics underwent significant expansion, growing its team by over 400% in the six years leading up to 2016. A pivotal moment in the company's journey came in February 2016, when it was announced that Biologics would be acquired by McKesson Specialty Health, a division of the healthcare giant McKesson Corporation. The acquisition was part of a larger $1.2 billion deal for McKesson that also included Vantage Oncology. For Biologics, this was a historic event that integrated their specialized services into McKesson's vast healthcare platform, promising to serve a wider network of patients and providers.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1994
- Headquarters
- Cary, United States
- Employees
- 295
- Open positions
- None listed
- Dealroom signal
- 57.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Biotech & Life Sciences, Pharmacy, Biotechnology, Oncology, Hard Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2016 | $0 | — | McKesson Surgical Solutions | — |
| LATE VC✓Equity / VC | Apr 2015 | $29M | $116M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Biologics is 21K monthly website visits, up 9030.4% over the last three months. Biologics's team grew 70.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
McKesson Surgical Solutions
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







